<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682782</url>
  </required_header>
  <id_info>
    <org_study_id>2020-516</org_study_id>
    <nct_id>NCT04682782</nct_id>
  </id_info>
  <brief_title>Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients</brief_title>
  <official_title>Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to determine whether a small-dose esketamine infusion can be used for pain&#xD;
      control in severe burn patients, and thereby reduce the total intra-operative opioid&#xD;
      requirement. Secondary objectives are to determine whether this low-dose esketamine infusion&#xD;
      will increase the stability of circulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative sufentanil</measure>
    <time_frame>24 hours</time_frame>
    <description>For all participants, the dose of intraoperative sufentanil will be recorded in micrograms and compared between the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>For all participants, blood pressure will be recorded and compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative heart rate</measure>
    <time_frame>24 hours</time_frame>
    <description>For all participants, heart rate will be recorded and compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative cardiac index</measure>
    <time_frame>24 hours</time_frame>
    <description>For all participants, cardiac index will be recorded and compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative recovery time</measure>
    <time_frame>24 hours</time_frame>
    <description>For all participants, the recovery time of spontaneous breathing will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Esketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive Esketamine (1 mg/ml) infused at 0.1 mg/kg/hour (0.1 ml/kg/h) throughout the operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .</description>
    <arm_group_label>Esketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All intubated adult burn patients( age&gt;18 ), presenting to the operating room;&#xD;
&#xD;
          -  Burn area&gt; 30%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to Esketamine or benzodiazepines&#xD;
&#xD;
          -  Esketamine or ketamine use in the preceding 24 hours&#xD;
&#xD;
          -  Increased intracranial pressure&#xD;
&#xD;
          -  Increased intraocular pressure&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Thyroid disorders&#xD;
&#xD;
          -  Seizures&#xD;
&#xD;
          -  Acute myocardial ischemia&#xD;
&#xD;
          -  Children (patients under age 18), prisoners, pregnant or breastfeeding women, patients&#xD;
             with psychosis, patients with developmental delay, and any condition which, in the&#xD;
             opinion of the investigator, would prevent full participation in this study or would&#xD;
             interfere with the evaluation of the trial endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min YAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingyu SHI, MD</last_name>
    <phone>+8613777564585</phone>
    <email>shiqinyu_001@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd affiliated hospital, School of Medicine, Zhejiang Universtiy, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyu SHI</last_name>
      <phone>+8613777564585</phone>
      <email>shiqinyu_001@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

